Nordic Nanovector ASA (OSE: NANO), a company focusing on the development
and commercialization of novel targeted therapeutics in haematology and
oncology, announces the formation of a new Scientific Advisory Board
(SAB). The SAB includes experts in haematology-oncology and cancer drug
development from leading academic/research institutions in the US and
Europe.
Nordic Nanovector CEO, Luigi Costa said: “I am delighted that Nordic
Nanovector has attracted such a high quality Scientific Advisory Board.
I am confident that its advice and guidance will prove invaluable as the
Company advances its development of Betalutin™ as a novel treatment for
non-Hodgkin lymphoma and of its pipeline in the coming years.“
The SAB will be chaired by:
• Prof. Timothy Illidge (UK): Professor of Targeted Therapy and Oncology
and Honorary Consultant in Oncology, University of Manchester and
Christie NHS Trust.
• Prof. Pierluigi Zinzani (Italy): Associate Professor of Hematology at
the Institute of Hematology “L. e A. Seràgnoli,” University of Bologna.
In addition, the SAB includes:
• Dr Arne Kolstad (Norway): Senior Consultant in Medical Oncology and
Radiotherapy at Oslo University Hospital Radiumhospitalet.
• Prof. Dolores Caballero (Spain): Head of Clinic and Transplant Unit at
the University Hospital, Salamanca.
• Prof. Stephen Schuster (USA): Robert and Margarita Louis-Dreyfus
Associate Professor of Chronic Lymphocytic Leukemia and Lymphoma,
Associate Professor of Medicine, and Associate Professor of Radiation
Oncology at the University of Pennsylvania School of Medicine.
• Prof. Armando Lopez-Guillermo (Spain): Senior Consultant at the
Department of Hematology in Hospital Clinic, Barcelona.
• Prof. Francesco D’Amore (Denmark): Clinical Professor in Malignant
Lymphoproliferative Diseases at the Department of Hematology, Aarhus
University Hospital.
• Prof. Mark Kaminski (USA): Professor of Hematology/Oncology,
University of Michigan.
• Prof. Wojciech Jurczak (Poland): Professor of Hematology at
Jagiellonian University, Cracow.
• Prof. Lorenz Trumper (Germany): Head of the Department of Hematology
and Medical Oncology, University Medical Center Göttingen.
• Prof. Morschhauser (France). Professor of Hematology and Head of the
Lymphoma Unit in the Department of Hematology at the Centre Hospitalier
Universitaire de Lille, in Lille.
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company’s lead clinical-stage product opportunity is
Betalutin™, the first in a new class of Antibody-Radionuclide-Conjugates
(ARC’s), designed to improve upon and complement current options for the
treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with
substantial unmet medical need and orphan drug opportunities,
representing a growing market worth over $12 billion by 2018.
Betalutin™ comprises a tumour-seeking anti-CD37 antibody conjugated to a
low intensity radionuclide (lutetium- 177). It has shown promising
efficacy and a favourable safety profile in a Phase 1 study, in a
difficult-to-treat NHL patient population. The Company is aiming at
rapidly developing Betalutin™ for the treatment of major types of NHL
with first approval anticipated by the end of 2018.
Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin™ in core markets,
while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its ARC pipeline to
treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
Forward-looking statements
This announcement may contain certain forward-looking statements and
forecasts based on uncertainty, since they relate to events and depend
on circumstances that will occur in the future and which, by their
nature, will have an impact on Nordic Nanovector’s business, financial
condition and results of operations. The terms “anticipates”, “assumes”,
“believes”, “can”, “could”, “estimates”, “expects”, “forecasts”,
“intends”, “may”, “might”, “plans”, “should”, “projects”, “will”,
“would” or, in each case, their negative, or other variations or
comparable terminology are used to identify forward-looking statement.
There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in a
forward-looking statement or affect the extent to which a particular
projection is realised. Factors that could cause these differences
include, but are not limited to, implementation of Nordic Nanovector’s
strategy and its ability to further grow, risks associated with the
development and/or approval of Nordic Nanovector’s products candidates,
ongoing clinical trials and expected trial results, the ability to
commercialise BetalutinTM, technology changes and new products in Nordic
Nanovector’s potential market and industry, the ability to develop new
products and enhance existing products, the impact of competition,
changes in general economy and industry conditions and legislative,
regulatory and political factors. No assurance can be given that such
expectations will prove to have been correct. Nordic Nanovector
disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.
This information was brought to you by Cision http://news.cision.com
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150521005621r1&sid=ntxv4&distro=nx&lang=en)
View source version on businesswire.com: http://www.businesswire.com/news/home/20150521005621/en/
Copyright Business Wire 2015